Post Hoc Analysis of Lung Function Improvement and Patient-Reported Outcomes With Revefenacin in Adults With Moderate-to-Very Severe COPD and Comorbid Anxiety or Depression

Revefenacin, a once-daily, nebulized, long-acting muscarinic antagonist approved in the United States for the maintenance of chronic obstructive pulmonary disease (COPD), significantly improves lung function and quality of life versus placebo in patients with moderate-to-very severe COPD. Comorbid a...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Chronic obstructive pulmonary diseases 2024-03, Vol.11 (2), p.196-205
Hauptverfasser:	Yohannes, Abebaw M, Iyer, Anand S, Clay, Candice, Cochran, Lauren, Chen, Xianyi, Lombardi, David A, Bhatt, Surya P
Format:	Artikel
Sprache:	eng
Schlagworte:	Origianl Research
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!